PLRZ
Polyrizon Ltd.NASDAQHealthcare$12.08-4.20%ClosedMarket Cap: $13.5M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.94
P/S
0.00
EV/EBITDA
-2.80
DCF Value
$0.81
FCF Yield
-25.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.1%
ROA
-19.2%
ROIC
-17.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-3.2M | $-1.96 |
| FY 2025 | $0.00 | $-3.3M | $-2.07 |
| Q2 2025 | $0.00 | $-88.50 | $-0.06 |
| Q1 2025 | $0.00 | $-88.50 | $-0.06 |
Trading Activity
Insider Trades
View AllIzraeli Tomerdirector, officer: Chief Executive Officer
SellWed Apr 01
Carmel Lirondirector
SellWed Apr 01
Adler Ozdirector
SellWed Apr 01
Carmel Lirondirector
SellTue Mar 31
Izraeli Tomerdirector, officer: Chief Executive Officer
SellTue Mar 31
Company Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
-6.06
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.